Double-blind study of VAH631 in patients with essential hypertension (factorial study)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220234

Enrollment

558

Registered

2006-04-21

Start date

2006-04-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

investigational material(s) Generic name etc : VAH631 INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational material : Oral

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria - Essential hypertension measured by mercury sphygmomanometer - Outpatients - Male or female aged 20 to 80 years old Exclusion criteria - Secondary hypertension or suspected of having secondary hypertension. - A history of malignant hypertension - Severe hypertension - Significant heart, renal, hepatic diseases or significant cerebrovascular disorder - Gout Other protocol-defined inclusion/exclusion criteria may apply

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Primary Outcomes: Change from baseline in diastolic blood pressure after 8 weeks Secondary Outcomes: Change from baseline in systolic blood pressure after 8 weeks; Diastolic blood pressure less than 90 mmHg or at least a 10 mmHg decrease in diastolic blood pressure after 8 weeks; Change from baseline in standing diastolic blood pressure after 8 weeks; Change from baseline in standing systolic blood pressure after 8 weeks; Adverse events and serious adverse events at each study visit for 8 weeks	—

Measure

Time frame

Primary Outcomes: Change from baseline in diastolic blood pressure after 8 weeks Secondary Outcomes: Change from baseline in systolic blood pressure after 8 weeks; Diastolic blood pressure less than 90 mmHg or at least a 10 mmHg decrease in diastolic blood pressure after 8 weeks; Change from baseline in standing diastolic blood pressure after 8 weeks; Change from baseline in standing systolic blood pressure after 8 weeks; Adverse events and serious adverse events at each study visit for 8 weeks

—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026